Go Deep
Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc. Common stock Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,081 | -0.5 | 10.54 | 0.00 | 41.23 |
| Oct 2026 | 18,243 | -0.6 | 12.14 | 0.00 | 47.47 |
| Oct 2026 | 16,894 | -0.7 | 14.69 | 0.00 | 57.30 |
| Oct 2026 | 15,166 | -0.7 | 14.54 | 0.00 | 56.80 |
| Oct 2026 | 14,947 | -0.7 | 14.96 | 0.00 | 58.42 |
| Oct 2026 | 15,636 | -0.6 | 13.65 | 0.00 | 53.17 |
| Oct 2026 | 16,223 | -0.6 | 12.53 | 0.00 | 48.72 |
Actuate Therapeutics, Inc. Common stock Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -4,866,635.0 | -5,625,749.0 | -4,553,953.0 | -5,407,470.0 |
| EPS | -0.2 | -0.2 | — | -0.2 |
Actuate Therapeutics, Inc. Common stock Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -22,227,852.0 | -27,285,328.0 | -24,744,620.0 | -20,159,401.0 |
| EPS | -1.1 | -3.3 | -1.3 | -1.3 |
Actuate Therapeutics, Inc. Common stock Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 14,035,910.0 | 9,318,448.0 | 2,995,566.0 | 20,483,056.0 |
| Total Liabilities | 6,111,907.0 | 9,214,262.0 | 102,622,079.0 | 95,788,488.0 |
| Total Equity | 7,924,003.0 | 104,186.0 | -99,626,513.0 | -75,305,432.0 |
Owes vs Owns
Actuate Therapeutics, Inc. Common stock owed $0.81 for every $1 it owned in Jun 2026, down from $4.68 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.81× | 0.44× | 0.99× | 34.3× | 4.68× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Actuate Therapeutics, Inc. Common stock Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.8%Other assets 6.2%
How it's funded — Dec 2025
Payables 10.9%Other liabilities 32.7%Shareholders' equity 56.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 13.2 | 8.6 | 3.0 | 20.4 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.9 | 0.7 | 0.0 | 0.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 1.5 | 1.9 | 3.4 | 2.1 |
| Other liabilities | 4.6 | 7.3 | 99.2 | 93.7 |
| Shareholders' equity | 7.9 | 0.1 | -99.6 | -75.3 |
| Net tangible assets | 7.9 | 0.1 | -99.6 | -75.3 |
Actuate Therapeutics, Inc. Common stock Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -19,206,253.0 | -21,842,648.0 | -21,625,167.0 | -17,794,093.0 |
| Financing Activities | 23,724,054.0 | 27,525,611.0 | 4,134,516.0 | 19,255,569.0 |